Regeneron Pharmaceuticals (REGN)
by Zacks Equity ResearchJuly 24, 2012 | Comments : 0 Recommended this article: (0)
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
We have increased our 2012 earnings estimates by $0.17 to $1.07 per share. Moreover, with three action dates and multiple pipeline related news lined up, the remainder of 2012 promises to be exciting for Regeneron, with a scope for significant stock price appreciation.
Consequently, we believe that the current price represents an attractive entry point for long-term investors. Based on 2012 sales estimates, the stock is trading at 10.8x, compared to the industry average of 4.2x. Our price target of $145.00 is based on P/S of 13.0x our 2012 sales estimate.
Please login to Zacks.com or register to post a comment.